CABLIVI use necessitates careful attention to the risk of hemorrhage, potential hypersensitivity reactions, and specific considerations for surgical interventions and concomitant medication use to ensure patient safety.

Precautions and Safety Measures for CABLIVI

A primary precaution with CABLIVI is the risk of hemorrhage; serious and even fatal bleeding events have been reported. This risk is amplified in patients with pre-existing coagulopathies or those receiving concurrent antiplatelet agents or anticoagulants, the concomitant use of which should be avoided if possible and monitored closely if deemed necessary. Treatment should be interrupted if clinically significant bleeding occurs. CABLIVI is contraindicated in patients with a history of severe hypersensitivity to caplacizumab-yhdp or its excipients. For elective surgeries, dental procedures, or other invasive interventions, CABLIVI should be withheld for at least 7 days prior. In emergency surgical situations, von Willebrand factor concentrate may be considered to correct hemostasis. Patients, including pregnant women who may face risks of maternal and fetal hemorrhage, and those with severe hepatic impairment (not formally studied but requires close bleeding monitoring), should be managed with caution.